Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
PDE4 Inhibitor Roflumilast for AD
Key Takeaways
- The evolution of atopic dermatitis treatments emphasizes nonsteroidal options, reducing corticosteroid dependency and targeting specific inflammatory pathways.
- Nonsteroidal treatments, like PDE4 inhibitors, offer effective modulation of immune responses with a favorable side effect profile.
Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.
- Can you provide an overview of the current landscape of topical treatments for atopic dermatitis and how these options, specifically nonsteroidal options, have evolved over the past decade?
- What is the mechanism of action of PDE4 inhibitors, and how do they specifically target the inflammatory pathways in atopic dermatitis?
Related Videos
Related Content
